| Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) NCT06054113 | Fase 2 | En marcha, sin reclutar |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL NCT04521231 | Fase 1/2 | En marcha, sin reclutar |
| Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia NCT04994717 | Fase 3 | En marcha, sin reclutar |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia NCT07134088 | Fase 1/2 | En marcha, sin reclutar |
| AUDAX NCT07223190 | Fase 3 | Aún sin reclutar |
| Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL) NCT06649006 | Fase 1 | Completado |
| Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) NCT04506086 | Fase 4 | Interrumpido |
| Leucemia linfoblástica aguda NCT04524455 | Fase 1 | Completado |
| Linfoma no Hodgkin NCT02961881 | Fase 1 | Completado |
| HARBOUR NCT03340766 | Fase 1 | Completado |
| Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL NCT02910063 | Fase 2/3 | Completado |
| Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) NCT03298412 | Fase 2 | Interrumpido |
| Leucemia linfoblástica aguda NCT03476239 | Fase 3 | Completado |
| Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) NCT02393859 | Fase 3 | Completado |
| Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma NCT03023878 | Fase 2 | Completado |
| Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia NCT02412306 | Fase 1/2 | Completado |
| Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) NCT02013167 | Fase 3 | Interrumpido |
| Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia NCT02000427 | Fase 2 | Completado |
| Leucemia linfoblástica aguda NCT01471782 | Fase 1/2 | Completado |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT01741792 | Fase 2 | Completado |
| BLAST NCT01207388 | Fase 2 | Completado |
| Leucemia linfoblástica aguda NCT01466179 | Fase 2 | Completado |
| Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) NCT01209286 | Fase 2 | Completado |
| Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL NCT00274742 | Fase 1 | Completado |
| Leucemia linfoblástica aguda NCT00560794 | Fase 2 | Completado |
| RIALTO NCT02187354 | no aplica | Ya no disponible |